• Policy
• 16 drugs including Venclexta receive reimbursement in 1H
• by Kim, Jung-Ju Jun 28, 2021 05:50am

• Company
• MET inhibitor ‘Tabrecta’ to overcome Tagrisso resistance?
• by Jun 28, 2021 05:50am

• Policy
• Billing for α-GPC is managed
• by Lee, Jeong-Hwan Jun 28, 2021 05:50am

• Policy
• The number of items has plummeted due to regulatory impact
• by Lee, Tak-Sun Jun 28, 2021 05:49am

• Company
• Intra-articular injection Conjuran can be reimbursed
• by Moon, sung-ho Jun 28, 2021 05:49am

• Company
• Will the new social distancing benefit the prescription mkt?
• by Chon, Seung-Hyun Jun 25, 2021 05:51am

• Company
• Telemisartan is excluded from impurity survey
• by Kim, Jin-Gu Jun 25, 2021 05:51am

• Policy
• NA LJC to review ‘1+3 bill for generics’ tomorrow
• by Lee, Jeong-Hwan Jun 25, 2021 05:51am

• Policy
• MFDS investigates impurities of Sartan and Varenicline
• by Lee, Tak-Sun Jun 25, 2021 05:50am

• Company
• Sillajen acquirer GFB seeks further partnership opportunity
• by Jun 24, 2021 05:55am